Skip to main content

Topical Calcineurin Inhibitors

Topical calcineurin inhibitors (TCIs) — tacrolimus (0.03% and 0.1% ointment) and pimecrolimus (1% cream) — serve primarily as second-line, steroid-sparing anti-inflammatory agents in urology and urogynecology. Their off-label genital uses include genital lichen sclerosus, vulvar / penile lichen planus, Zoon balanitis, and other anogenital inflammatory dermatoses.[1][2][3] A novel investigational application is intravesical tacrolimus for refractory IC/BPS.

The defining advantage over topical corticosteroids is no risk of skin atrophy — a critical property in the thin, sensitive anogenital skin, when individualized long-term treatment is needed.[3][4]

For related agents, see High-potency topical corticosteroids, Intralesional corticosteroids, Platelet-rich plasma, Intravesical IC/BPS agents, and the clinical Lichen sclerosus article.

US labeling: these products are second-line atopic-dermatitis therapies, not FDA-approved genital LS treatments. Tacrolimus 0.03% is the labeled strength for ages 2–15; 0.1% is for adults (≥16). Neither tacrolimus nor pimecrolimus is labeled for children under two. Genital use requires deliberate off-label selection.[7][35]

Mechanism​

TCIs inhibit calcineurin, a calcium-dependent phosphatase required for NFAT-mediated T-cell activation. The resulting block suppresses transcription of IL-2, IL-3, IL-4, IFN-γ, and TNF.[5][6] Additional mast-cell stabilization and suppression of histamine release contribute to the antipruritic effect.[7][8]

Critically, TCIs do not affect collagen synthesis and therefore do not cause skin atrophy, striae, telangiectasia, or the rebound effects seen with long-term corticosteroid use — the pharmacologic basis for their role as steroid-sparing maintenance agents in chronic genital dermatoses.[3][4]

Vulvar and anogenital lichen sclerosus — primary indication​

The most extensively studied urogynecologic application.

Second-line positioning: the German S3 guideline supports selected TCI use when topical corticosteroids are insufficient or contraindicated. These remain off-label genital treatments; supervised corticosteroid treatment is first line, including in children.[9][36]

Evidence​

StudyDesignFinding
Hengge 2006Phase II multicenter (n = 84) — tacrolimus 0.1% BID × 16 wk43% clearance of active LS + 34% partial resolution; significant reduction in lesional area and symptom scores; only 9% recurred during 18-mo follow-up[10]
Funaro 2014 RCTDouble-blind clobetasol 0.05% vs tacrolimus 0.1%Both reduced symptoms; clobetasol significantly more effective for complete absence of signs/symptoms (p = 0.002)[11]
Chi 2011 CochraneSystematic reviewPimecrolimus comparable to clobetasol for symptom relief; less effective for gross clinical improvement[12][13]
Mazzilli 2018Pediatric case series — tacrolimus 0.03%Well-tolerated; significant improvement in itching, pain, and constipation[14]

Clinical position​

Consider TCIs after reassessing the diagnosis, application technique, adherence and possible neoplasia in disease that is not responding. Appropriate uses include corticosteroid intolerance or contraindication, and selected inadequate response. Do not routinely replace effective corticosteroid maintenance, or interpret LS-related atrophy as proof of steroid injury. Pediatric use requires specialist selection rather than substitution based on steroid fear alone.[15][16][36]

Clobetasol 0.05% ointment remains first-line for induction; TCIs are second-line and steroid-sparing. See High-potency topical corticosteroids for the induction framework.

Penile lichen sclerosus / BXO​

Shieh 2024 J Urol systematic review — topical corticosteroids remain the mainstay of conservative management for penile / urethral LS, with tacrolimus supported as an alternative or adjuvant when escalation is needed.[17]

Circumcision can resolve foreskin-limited pediatric BXO, but meatal or urethral disease may persist. Evidence for topical immunomodulators preventing recurrent meatal stenosis is limited; they do not replace follow-up or management of functional obstruction.[18]

Kim 2012 — tacrolimus in anogenital LS: 90% objective response (50% complete, 40% partial). However, relapse was common (6/9) during long-term follow-up, underscoring the need for ongoing maintenance therapy.[19]

Vulvar and genital lichen planus​

ACOG Level B: TCIs for LP resistant to topical corticosteroid therapy.[9]

  • Byrd 2004 — retrospective data on tacrolimus for recalcitrant vulvar LP showed effective symptom control, but benefits were not sustained after discontinuation — individualized ongoing treatment may be needed[20]
  • Goldstein 2009 — both tacrolimus and pimecrolimus supported as effective and well-tolerated second-line options for genital LP[3]

Other anogenital dermatoses​

ConditionTCI roleEvidence
Plasma cell (Zoon) balanitisTacrolimus 0.1% — good results within 4 weeksKyriakou 2014 series (n = 9)[21][22]
Genital psoriasisOff-label steroid-sparing treatment; short-term benefit in studies mixing facial, inverse and genital sitesAmiri 2023 SR (24 studies, five RCTs); no single pooled genital clearance rate[23][24]
Perianal eczemaTacrolimus 0.1% BID × 2 weeksSchauber 2009 — clinical improvement in all patients[25]
Resistant anogenital pruritusTacrolimus — likely via TRPV1 activationYosipovitch 2013[26]

Intravesical tacrolimus for IC/BPS — investigational​

A novel off-label application under active investigation.

  • Mishra 2019 pilot (n = 24 intractable IC/BPS) — tacrolimus dissolved in DMSO/sterile water instilled intravesically; improvement in 54% (13/24) over 6–63-month follow-up. Serum tacrolimus levels remained safe; no significant systemic AEs[27]
  • 2025 global consensus lists tacrolimus among immunotherapies for IC/BPS, alongside cyclosporine[28]

Cyclosporine A has stronger evidence in IC/BPS based on Di 2021 network meta-analysis and Giannantoni 2012 European Urology systematic review — intravesical tacrolimus remains early-stage off-label pending controlled trials.[29][30]

See Intravesical IC/BPS agents for the complete instillation armamentarium.

Genital graft-versus-host disease — caution​

  • Choi 2001 case series (n = 18 chronic cutaneous GVHD) — topical tacrolimus showed response in ~70%[4]
  • Elad 2003 — topical tacrolimus as a novel treatment alternative for cutaneous chronic GVHD[31]
  • Rostagno 2022 scoping review concluded no topical intervention has strong evidence in GVHD — topical therapies serve as adjuncts to systemic treatment[32]

FDA label caution: avoid topical tacrolimus in cutaneous GVHD due to skin-barrier defects that can drive systemic absorption. Toxic tacrolimus levels have been reported when occlusive dressings are used concurrently.[33][34]

Safety​

Adverse effects​

ConcernDetails
Local irritationBurning / stinging / pruritus — most common in first days; subsides with continued use[5][6][7]
FDA Black-Box WarningLong-term safety is unestablished; rare malignancies have been reported without established causality. Avoid continuous long-term use as directed by the label[6][4]
No skin atrophyKey advantage over corticosteroids for chronic anogenital use[3]
Systemic absorptionMinimal through intact skin; caution with skin-barrier defects (GVHD, Netherton's), occlusive dressings, or large BSA application[7][33]
Avoid on premalignant / malignant lesionsPer FDA label; CTCL may mimic dermatitis[7]
Sun protectionRecommended during therapy based on photocarcinogenicity data[4]

LS-specific observational evidence: a large 2026 propensity-matched study found no increased malignancy signal with TCI exposure. This does not prove long-term safety or equivalence to clobetasol. See clinical LS malignancy risk for the study and its limits.

Tacrolimus vs pimecrolimus​

AgentStrengthPractical differentiators
Tacrolimus ointment 0.03% / 0.1%0.1% is the standard adult dose; 0.03% used in pediatricsStronger immunomodulatory effect; more likely effective in LS, LP, Zoon balanitis; more burning / stinging on application
Pimecrolimus cream 1%Single strengthBetter tolerated (less burning); less effective than clobetasol for gross LS improvement; selected second-line LS use when appropriate corticosteroid treatment cannot be used[12][13]

Prescribing summary​

ConditionFirst-lineTCI roleTCI regimenDuration
Lichen sclerosus (vulvar or penile)Clobetasol 0.05% ointmentSelected off-label second-line useSpecialist-directed tacrolimus, commonly 0.1% in adultsReassess and reduce frequency after control; not automatic indefinite BID[9][10]
Vulvar / genital lichen planusClobetasol 0.05% ointmentSecond-line when steroid-refractoryTacrolimus 0.1% BIDOngoing; symptoms often recur on discontinuation[9][20]
Plasma cell (Zoon) balanitisTrimovate or moderate TCS; circumcision curativeAlternative for recalcitrant / circumcision-declinedTacrolimus 0.1% BID × 4 weeksUntil resolution[21]
Genital psoriasisLow-potency TCSSteroid-sparing maintenanceTacrolimus 0.1% BID or pimecrolimus 1% BIDIntermittent / maintenance[23][24]
Perianal eczemaLow-potency TCSAlternative if corticosteroid refractoryTacrolimus 0.1% BID × 2 weeksShort course[25]
Anogenital pruritus (refractory)Address cause; low-potency TCSAdjunctive for resistant casesTacrolimus 0.1% BIDUntil symptomatic improvement[26]
IC/BPS (refractory)Individualized AUA-guideline careInvestigationalIntravesical tacrolimus (Mishra protocol)Per trial protocol[27]
Cutaneous GVHD (genital)Systemic therapyCaution — risk of systemic absorptionTacrolimus 0.1% — avoid occlusion; monitor levels if usedAdjunct only[33][34]

Evidence Summary​

IndicationEvidence and limitsKey source
Vulvar LS (general)Small RCTs and uncontrolled studies; clobetasol remains preferredChi 2011 Cochrane[12]; Funaro 2014[11]; Hengge 2006[10]
Penile LSSystematic review; limited direct comparative evidenceShieh 2024[17]; Kim 2012[19]
Pediatric LSSmall case seriesMazzilli 2018[14]
Vulvar lichen planusRetrospective series and guideline adviceByrd 2004[20]; ACOG 224[9]
Plasma cell balanitisSmall case seriesKyriakou 2014[21]
Genital psoriasisSystematic review; limited direct comparative evidenceAmiri 2023[23]
Intravesical tacrolimus for IC/BPSUncontrolled pilotMishra 2019[27]
GVHDCase series and toxicity reports; label cautionChoi 2001[4]; Olson 2014 toxicity report[34]

Clinical Positioning​

  • TCIs are second-line, steroid-sparing agents for chronic anogenital inflammatory dermatoses — their defining feature is no skin atrophy, which can support selected intermittent use in chronic disease.[3][9]
  • Clobetasol remains first-line in LS. Do not automatically switch every controlled patient to tacrolimus; assess disease activity, steroid tolerance and the limited long-term genital TCI evidence.[11][12]
  • In pediatric LS, corticosteroids remain first line. Small TCI series support selected specialist use, but do not establish superior long-term safety or efficacy over appropriately supervised corticosteroid treatment.[9][14]
  • Counsel about application-site burning — the dominant early AE; reassure that it subsides with continued use over 1–2 weeks to improve adherence.[5][6]
  • Explain the boxed warning accurately: malignancy causality is unestablished, but the label does not certify long-term safety. Avoid continuous indefinite application, suspicious lesions and immunocompromised use without specialist assessment.[7]
  • Pimecrolimus is less effective than clobetasol for LS gross improvement — consider it only as a selected second-line option, with response monitoring.[12][13]
  • In Zoon balanitis, circumcision remains curative; tacrolimus is the best-supported non-surgical option for patients declining or unable to undergo circumcision.[21]
  • Intravesical tacrolimus for IC/BPS is investigational (Mishra 2019 — 54% response). Cyclosporine has stronger evidence in this setting; do not default to intravesical tacrolimus as routine care outside a properly evaluated specialist research protocol.[27][29]
  • Avoid topical tacrolimus on broken skin or under occlusion — systemic absorption can reach toxic levels (GVHD case reports). In cutaneous GVHD specifically, the FDA cautions against its use.[33][34]
  • Avoid application on premalignant or malignant lesions. Evaluate unresponsive or atypical vulvar lesions with biopsy before escalating immunomodulatory therapy — CTCL and early vulvar SCC can masquerade as dermatitis or LS.[7][9]
  • Sun protection during treatment is reasonable given photocarcinogenicity signals.[4]

See Also​

References​

1. Cury Martins J, Martins C, Aoki V, et al. "Topical tacrolimus for atopic dermatitis." Cochrane Database Syst Rev. 2015;(7):CD009864. doi:10.1002/14651858.CD009864.pub2

2. Vakharia PP, Silverberg JI. "New and emerging therapies for paediatric atopic dermatitis." Lancet Child Adolesc Health. 2019;3(5):343–353. doi:10.1016/S2352-4642(19)30030-6

3. Goldstein AT, Thaçi D, Luger T. "Topical calcineurin inhibitors for the treatment of vulvar dermatoses." Eur J Obstet Gynecol Reprod Biol. 2009;146(1):22–29. doi:10.1016/j.ejogrb.2009.05.026

4. Choi CJ, Nghiem P. "Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients." Arch Dermatol. 2001;137(9):1202–1206. doi:10.1001/archderm.137.9.1202

5. Eichenfield LF, Tom WL, Berger TG, et al. "Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies." J Am Acad Dermatol. 2014;71(1):116–132. doi:10.1016/j.jaad.2014.03.023

6. Prucha H, Schnopp C, Akdis C, et al. "Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema." Expert Opin Drug Metab Toxicol. 2013;9(11):1507–1516. doi:10.1517/17425255.2013.819343

7. DailyMed. Tacrolimus ointment prescribing information, updated April 15, 2026. Label. Accessed September 12, 2026.

8. Rallis E, Korfitis C, Gregoriou S, Rigopoulos D. "Assigning new roles to topical tacrolimus." Expert Opin Investig Drugs. 2007;16(8):1267–1276. doi:10.1517/13543784.16.8.1267

9. American College of Obstetricians and Gynecologists. "Diagnosis and management of vulvar skin disorders: ACOG Practice Bulletin Summary, Number 224." Obstet Gynecol. 2020;136(1):222–225. doi:10.1097/AOG.0000000000003945

10. Hengge UR, Krause W, Hofmann H, et al. "Multicentre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus." Br J Dermatol. 2006;155(5):1021–1028. doi:10.1111/j.1365-2133.2006.07446.x

11. Funaro D, Lovett A, Leroux N, Powell J. "A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus." J Am Acad Dermatol. 2014;71(1):84–91. doi:10.1016/j.jaad.2014.02.019

12. Chi CC, Kirtschig G, Baldo M, et al. "Topical interventions for genital lichen sclerosus." Cochrane Database Syst Rev. 2011;(12):CD008240. doi:10.1002/14651858.CD008240.pub2

13. Chi CC, Kirtschig G, Baldo M, et al. "Systematic review and meta-analysis of randomized controlled trials on topical interventions for genital lichen sclerosus." J Am Acad Dermatol. 2012;67(2):305–312. doi:10.1016/j.jaad.2012.02.044

14. Mazzilli S, Diluvio L, Di Prete M, et al. "Tacrolimus 0.03% ointment for treatment of paediatric lichen sclerosus: a case series and literature review." J Int Med Res. 2018;46(9):3724–3728. doi:10.1177/0300060518778219

15. De Luca DA, Papara C, Vorobyev A, et al. "Lichen sclerosus: the 2023 update." Front Med. 2023;10:1106318. doi:10.3389/fmed.2023.1106318

16. Borghi A, Corazza M. "Novel therapeutic approaches and targets for treatment of vulvar lichen sclerosus." Curr Pharm Biotechnol. 2021;22(1):99–114. doi:10.2174/1389201021666200516154310

17. Shieh C, Hakam N, Pearce RJ, et al. "Conservative management of penile and urethral lichen sclerosus: a systematic review." J Urol. 2024;211(3):354–363. doi:10.1097/JU.0000000000003804

18. Nguyen ATM, Holland AJA. "Balanitis xerotica obliterans: an update for clinicians." Eur J Pediatr. 2020;179(1):9–16. doi:10.1007/s00431-019-03516-3

19. Kim GW, Park HJ, Kim HS, et al. "Topical tacrolimus ointment for the treatment of lichen sclerosus, comparing genital and extragenital involvement." J Dermatol. 2012;39(2):145–150. doi:10.1111/j.1346-8138.2011.01384.x

20. Byrd JA, Davis MD, Rogers RS. "Recalcitrant symptomatic vulvar lichen planus: response to topical tacrolimus." Arch Dermatol. 2004;140(6):715–720. doi:10.1001/archderm.140.6.715

21. Kyriakou A, Patsatsi A, Patsialas C, Sotiriadis D. "Therapeutic efficacy of topical calcineurin inhibitors in plasma cell balanitis: case series and review of the literature." Dermatology. 2014;228(1):18–23. doi:10.1159/000357153

22. Moreno-Arias GA, Camps-Fresneda A, Llaberia C, Palou-Almerich J. "Plasma cell balanitis treated with tacrolimus 0.1%." Br J Dermatol. 2005;153(6):1204–1206. doi:10.1111/j.1365-2133.2005.06945.x

23. Amiri D, Schwarz CW, Gether L, Skov L. "Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital psoriasis: a systematic review." Acta Derm Venereol. 2023;103:adv00890. doi:10.2340/actadv.v103.6525

24. Armstrong AW, Read C. "Pathophysiology, clinical presentation, and treatment of psoriasis: a review." JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006

25. Schauber J, Weisenseel P, Ruzicka T. "Topical treatment of perianal eczema with tacrolimus 0.1%." Br J Dermatol. 2009;161(6):1384–1386. doi:10.1111/j.1365-2133.2009.09345.x

26. Yosipovitch G, Bernhard JD. "Chronic pruritus." N Engl J Med. 2013;368(17):1625–1634. doi:10.1056/NEJMcp1208814

27. Mishra NN, Riedl C, Shah S, Pathak N. "Intravesical tacrolimus in treatment of intractable interstitial cystitis/bladder pain syndrome — a pilot study." Int J Urol. 2019;26(Suppl 1):68–72. doi:10.1111/iju.13978

28. Buford K, Peters KM, Riedl C, et al. "Global consensus on interstitial cystitis/bladder pain syndrome: an update on therapeutic treatments." Neurourol Urodyn. 2025. doi:10.1002/nau.70106

29. Di XP, Luo DY, Jin X, et al. "Efficacy and safety comparison of pharmacotherapies for interstitial cystitis and bladder pain syndrome: a systematic review and Bayesian network meta-analysis." Int Urogynecol J. 2021;32(5):1129–1141. doi:10.1007/s00192-020-04659-w

30. Giannantoni A, Bini V, Dmochowski R, et al. "Contemporary management of the painful bladder: a systematic review." Eur Urol. 2012;61(1):29–53. doi:10.1016/j.eururo.2011.07.069

31. Elad S, Or R, Resnick I, Shapira MY. "Topical tacrolimus — a novel treatment alternative for cutaneous chronic graft-versus-host disease." Transpl Int. 2003;16(9):665–670. doi:10.1007/s00147-003-0594-2

32. Rostagno E, Campanati A, Mordini N, et al. "Phototherapy and topical treatments for cutaneous graft-vs-host disease in haematopoietic stem cell transplantation patients: a scoping review." J Eur Acad Dermatol Venereol. 2022;36(7):1003–1015. doi:10.1111/jdv.18074

33. DailyMed. Tacrolimus ointment prescribing information, updated April 15, 2026: skin-barrier disorders and GVHD precautions. Label. Accessed September 12, 2026.

34. Olson KA, West K, McCarthy PL. "Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease." Pharmacotherapy. 2014;34(6):e60–e64. doi:10.1002/phar.1418

35. Bausch Health. Elidel (pimecrolimus) Cream 1% prescribing information. Label. Accessed September 12, 2026.

36. Kirtschig G, Woelber L, Günthert A, et al. "Evidence- and consensus-based guideline on lichen sclerosus." J Dtsch Dermatol Ges. 2026;24(4):566–584. doi:10.1111/ddg.70000. Full German S3 guideline, June 2025.